Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Advancing Primatology Through Germ Cell Research and Genetic Modification Techniques
Published on: July 5, 2024
[Hormonal treatment for menopause and arterial risk]
François Gueyffier1, Catherine Cornu
1Centre d'investigation clinique et service de pharmacologie clinique, EA3736, hôpital Louis-Pradel, Hospices civils de Lyon, 69677 Bron Cedex.
Abstract:
Is hormonal atmosphere before menopause the cause of the lower risk of coronary heart disease in women? Big clinical trials do not validate this hypothesis, however simple and attractive: in 5 primary or secondary prevention trials, estrogens alone or in association with progestatives to near 32000 women after menopause, do not leave hope for a significant reduction of coronary risk, and show in contrast an 30% increase of stroke risk. These results highlight the crucial importance of clinical trials to validate therapeutic models. The remaining hypotheses on the nature of hormonal treatments and the administration route must follow the same validation process. The prescription of hormonal treatment for menopause illustrates the importance of informed decision including individualised estimate of the risk to benefit ratio.
More Related Videos
05:32Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
Published on: August 11, 2023
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Related Concept Videos
Menopause
Types of Hormones
Hormonal Regulation
Hormonal Regulation
Plant Hormones
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...